Apoptosis and immaturity in acute myeloid leukemia

Hematology

Volumn 10, Issue 1, 2005, Pages 25-34

  Del Principe, Maria Ilaria ^a   Del Poeta, Giovanni ^a   Venditti, Adriano ^a   Buccisano, Francesco ^a   Maurillo, Luca ^a   Mazzone, Carla ^a   Bruno, Antonio ^a   Neri, Benedetta ^a   Consalvo, Maria Irno ^a   Lo Coco, Francesco ^a   Amadori, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Acute myeloid leukemia; Apoptosis; Immaturity; Prognosis; Targeted therapies

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 2 CYANO 3,12 DIOXOOLEAN 1,9 DIEN 28 OIC ACID METHYL ESTER; 2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOPTOSIS INDUCING FACTOR; ARSENIC TRIOXIDE; CD133 ANTIGEN; CD34 ANTIGEN; CEP 701; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; GEMTUZUMAB OZOGAMICIN; IMATINIB; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; RETINOIC ACID; SEMAXANIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL MATURATION; DRUG MECHANISM; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; LEUKEMIA REMISSION; MITOCHONDRION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; TREATMENT FAILURE;

ACUTE DISEASE; APOPTOSIS; CELL DIFFERENTIATION; HUMANS; LEUKEMIA, MYELOID; MITOCHONDRIAL PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 23244458293     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330400020454     Document Type: Article

References (89)

1. Champlin R, Gale RP. Acute myelogenous leukemia: recent advances in therapy. Blood 1987;69:1551-1562.
2. Taylor PR, Reid MM, Stark AN, Brown N, Hamilton PJ, Proctor SJ. De novo acute myeloid leukemia in patients over 55-years old: a population based study of incidence, treatment and outcome. Leukemia 1995;9:231-237.
3. Stasi R, Del Poeta G, Masi M, et al. Incidence of chromosome abnormalities and clinical significance of karyotype de novo acute myeloid leukemia. Cancer Genet Cytogenet 1993;67:28-34.
4. Kerr JF, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994;73:2013-2026.
5. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-1316.
6. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309-1312.
7. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37-43.
8. Kothakota S, Azuma T, Reinhard C, et al. Caspase-3 generated fragment of gelsolin: effector of morphological changes in apoptosis. Science 1997;278:294-298.
9. Liu X, Zhou H, Slaughter C, Wang X. DFF, a heterodimeric protein that functions downstream of caspase 3 to trigger DNA fragmentation during apoptosis. Cell 1997;89:175-184.
10. Nunez G, Benedict MA, Hu Y, Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene 1998;17:3237-3245.
11. Rokhin OW, Glover RA, Cohen MB. Fas mediated apoptosis in human prostate carcinoma cell lines occurs via activation of caspase-8 and caspase-7. Cancer Res 1998;58:5870-5875.
12. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from the mitochondria: a primary site for bcl-2 regulation of apoptosis. Science 1997;275:1132-1136.
13. Saleh A, Srinivasula SM, Acharay S, Fishel R, Alnemri ES. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for pro-caspase-9 activation. J Biol Chem 1999;274:17941-17945.
14. Narita M, Shimizu S, Ito T, et al. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci USA 1998;95:14681-14686.
15. Brenner C, Cadou H, LaViera H, et al. Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. Oncogene 2000;19:329-336.
16. Oltvai ZN, Milliman CL, Korsmeyer K. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619.
17. Borner C. Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem 1996;271:12695-12698.
18. Huang DCS, O'Reilly LA, Strasser A, Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 1997;16:4628-4638.
19. Zhou P, Qian L, Kozopas K, Craig R. MCL-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 1997;89:630-643.
20. Kaufmann S, Karp J, Svingen PA, et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998;91:991-1000.
21. Stoetzer OJ, Nussler V, Darsow M, et al. Association of bcl-2, bax, bcl-xl and interleukin-1-beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia 1996;10:518-522.
22. Campos L, Rouault J-P, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia is associated with poor response to chemotherapy. Blood 1993;81:3091-3096.
23. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995;92:4507-4511.
24. Haldar S, Chintapalli J, Croce CM. Taxol induces Bcl-2 phosphorilation and death of prostate cancer cells. Cancer Res 1996;56:1253-1255.
25. Ito T, Deng X, Carr B, May WS. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997;272:11671-11673.
26. Srivastava R, Mi Q, Hardwick J, Longo D. Deletion of the loop region of Bcl-2 completely blocks palcitaxel-induced apoptosis. Proc Natl Acad Sci USA 1999;96:3775-3780.
27. Hu ZB, Minden MD, McCulloch EA. Phosphorylation of Bcl-2 after exposure of human leukemic cells to retinoic acid. Blood 1998;92:1768-1775.
28. Wang HG, Pathan N, Ethell IM, et al. Ca2 + -induced apoptosis through calcineurin dephosphorylation of BAD. Science 1999;284:339-343.
29. Charpin C, Garcia S, Bonnier P, et al. Bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: correlations with 10-year follow-up. J Clin Oncol 1998;16:2025-2031.
30. Coustan-Smith E, Kitanaka A, Pui C, et al. Clinical relevance of Bcl-2 overexpression in childhood acute lymphoblastic leucemia. Blood 1996;87:1140-1146.
31. Kornblau SM, Vu HT, Ruvolo P, et al. Bax and PKCa modulate the prognostic impact of Bcl-2 expression in acute myelogenous leukaemia. Clin Cancer Res 2000;6:1401-1409.
32. Ong Y, McMullin M, Bailie K, Lappin TRJ, Jones F, Irvine A. High bax expression is a good prognostic indicator in acute myeloid leukaemia. Br J Hematol 2000;111:182-189.
33. Del Poeta G, Venditti A, del Principe MI, et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003;101:2125-2131.
34. Macedo A, San Miguel JF, Vidriales MB, et al. Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J Clin Pathol 1996;49:15-18.
35. Willman CL. Immunophenotyping and cytogenetics in older adults with acute myeloid leukaemia: significance of expression of the multidrug resistance gene-1(MDR1). Leukemia 1996;10:S33-S35.
36. Bradbury DA, Zhu YM, Russel NH. Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Leuk Lymphoma 1997;24:221-228.
37. Wuchter C, Karawajew L, Ruppert V, et al. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia 1999; 13: 1943-1953.
38. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP. Pgp RP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998;91:4480-4488.
39. Kanda Y, Hamaki T, Yamamoto R, Chizuka A, Suguro M, Matsuyama T, et al. The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: an overview of 2483 patients from 22 studies. Cancer 2000;88:2529-2533.
40. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, et al. Expression of Bcl-2 related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 1999;13:1881-1892.
41. Bradbury DA, Russel NH. Comparative quantitative expression of bcl-2 by normal and leukaemic myeloid cells. Br J Haematol 1995;91:374-379.
42. Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis with Bcl-2 protein expression in acute myeloid leukaemia. Blood l997;89:243-255.
43. Lauria F, Raspadori D, Rondelli D, Ventura MA, Fiacchini M, Visani G, et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia 1997;11:2075-2078.
44. Maung ZT, McLean FR, Reid MM, Pearson AD, Proctor SJ, Hamilton PJ, et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol 1994;88:105-109.
45. Van Stijn A, Van der Pol MA, Kok A, et al. Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leucemia. Haematologica 2003;88:497-508.
46. Stahnke K, Eckhoff S, Mohr A, Meyer LH, Debatin KM. Apoptosis induction in peripheral leukaemia cells by remission induction treatment in vivo: selective depletion and apoptosis in a CD34+ subpopulation of leukemia cells. Leukemia 2003;17:2130-2139.
47. Suarez L, Vidriales MB, Garcia-Larana J, Lopez A, Martinez R, Martin-Reina V, et al. Multiparametric analysis of apoptotic and multidrug resistano phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukaemia. Haematologica 2001;86:1287-1295.
48. Porwitt-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia 1995;9:1191-1198.
49. Drach D, Zhao S, Drach J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992;80:2729-2734.
50. Delia D, Aiello A, Soligo D, et al. Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 1992;79:1291-1298.
51. Pisani F, Del Poeta G, Aronica G, Venditti A, Caravita T, Amadori S. In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts. Ann Hematol 1997;75:145-147.
52. Maurillo L, Del Poeta G, Venditti A, Buccisano F, Battaglia A, Santinelli S, et al. Quantitative analysis of Fas and bcl-2 expression in hematopoietic precursors. Haematologica 2001;86:237-243.
53. Ahmed N, Sammons J, Hassan HT. Bcl-2 protein in human myeloid leukaemia cells and its down-regulation during chemotherapy-induced apoptosis. Oncol Rep 1999;6:403-407.
54. Campos L, Sabido O, Viallet A, Vasselon C, Guyotat D. Expression of apoptosis-controlling proteins in acute leukemia cells. Leuk Lymphoma 1999;33:499-509.
55. Kohler T, Schill C, Deininger MW, et al. High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML). Leukemia 2002;16:22-29.
56. Del Poeta G, Del Principe MI, Buccisano F, et al. Clinical significance of spontaneous apoptosis is independent from immaturity in acute myeloid leukemia (AML). Blood 2003;102:100a.
57. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-542.
58. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 1989;49:5870-5878.
59. Herr I, Debatin K-M. Cellular stress response and apoptosis in cancer therapy. Blood 2001;98:2603-2614.
60. Tallman MS. Therapy of acute promyelocytic leukaemia: all-trans retinoic acid and beyond. Leukemia 1998;12:S37-S40.
61. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukaemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukaemia patients. Blood 1999;94:3315-3324.
62. Nabhan C, Tallman MS. Early Phase I/II Trials with Gentuzumab Ozogamicin (Mylotarg® in Acute Myeloid Leukemia. Clin Lymphoma 2002;2:S19-S23.
63. Walter RB, Raden BW, Cronk MR, et al. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gentuzumab ozogamicin. Blood 2004;103:4276-4284.
64. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Investig 1999;104:155-162.
65. Altucci L, Rossin A, Raffelsberger W, et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001;7:680-686.
66. Nieda M, Nicol A, Koezuka Y, et al. TRAIL expression by activated human CD4(+) Valpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 2001;97:2067-2074.
67. Ito Y, Pandey P, Place A, et al. The novel triterpenoid 2-cyano3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Diff 2000;11:261-267.
68. Konopleva M, Tsao T, Ruvolo P, et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 2002;99:326-335.
69. Suh WS, Kim YS, Schimmer AD, et al. Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitisation to TRAIL. Leukemia 2003;17:2122-2129.
70. Motoyama N, Wang F, Roth KA, et al. Massive cell death of immature haematopoietic cells and neurons in bcl-x-deficient mice. Science 1995;267:1506-1510.
71. Park J, Bernstein I, Hockenberry DM. Primitive human haematopoietic precursors express Bcl-x but not Bcl-2. Blood 2001;86:868-876.
72. Holinger EP, Chittenden T, Lutz RJ. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J Biol Chem 1999;274:13298-13304.
73. Wang J, Zhang Z, Choksi S, et al. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res 2000;60:1498-1502.
74. Fenton M, Bone N, Sinclain AJ. The efficient and rapid import into primary B and T lymphocytes and a lymphoblastoid cell line. J. Immunol Methods 1998;212: 41-48.
75. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction delivery of a biologically active protein into the mouse. Science 1999;285:156-159.
76. Wang J, Liu D, Zhang Z, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000;97:7124-7129.
77. Konopleva M, Tari AM, Estrov Z, et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leucemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 2000;95:3929-3938.
78. Waters JS, Webb A, Cunningham D, et al. Phase 1 clinical and parmacokinetis study of bcl-2 anti-sense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000;18:1812-1823.
79. Milella M, Estrov Z, Kornblau SM, et al. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukaemia. Blood 2002;99:3461-3464.
80. Fang G, Kim C, Perkins C, et al. CG57148B (STI571) induces differentiation and apoptosis and sensitises Bcr-Abl-positive human leukemic cells to apoptosis due to antileukemic drugs. Blood 2000;96:2246-2253.
81. Druker B, Sawyers C, Kantarjian HM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
82. Schmidt-Arras D, Schwable J, Bohmer FD, Serve H. Flt3 receptor tyrosine kinase as a drug target in leukemia. Curr Pharm Des 2004;10:1867-1883.
83. Brown P, Meshinchi S, Levis M, et al. Pediatric AML samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood 2004;104:1841-1849.
84. George P, Bali P, Cohen P, et al. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukaemia cells with mutant FLT-3. Cancer Res 2004;64:3645-3652.
85. Jarvis D, Turner AJ, Povirk LF, Traylor RS, Grant S. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Proc Natl Acad Sci USA 1994;54:1707-1714.
86. Koh H, Lee KH, Kim D, Kim S, Kim J, Chung J. Inhibition of Akt and ist anti-apoptotic activities by tumor necrosis factor-induced PRK2 cleavage. J Biol Chem 2000;275:34451-34458.
87. Estrov Z, Shishodia S, Faderl S, et al. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 2003;102:987-995.
88. Gozzini A, Rovida E, Dello Sbarba P, et al. Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. Cancer Res 2003;63:8955-8961.
89. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1995;5:1032-1038.